Cumberland outlines plan to fund operations for over 5 years as it prepares rolling NDA submission for ifetroban in DMD
At a glance
- $CPIX today+11.3%last $5.80
- Vs industry peers+12.53 pts6-peer median −1.20% · far ahead
- Since Nov 10+8.61%from the first trade after the story
- 52-week range37.5% below high$1.85 – $9.28
- Cash runway~63.9 yrs$80.6M cash ÷ $105K/mo burn · 10-Q
- Coverage0 this week5 in 30 days · quieter than usual
Nothing reported about cumberland across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Policy shifts the whole healthcare aisle; trial data shifts one company. Knowing which kind of story this is helps.
- How the stock is trading: $CPIX +11.32% in the latest session.
- Timing: It was published after the close, so the day's move was settled before the story existed. The next session is the first that could react.
Where the stock stands
Cumberland Pharmaceuticals ($CPIX) jumped 11.32% to $5.80 in the latest session. Over the past month it is down 13.4%. It now sits 38% under the 52-week high of $9.28 and 214% above the year's low of $1.85. The year's high was 5.0 times its low, which makes double-digit swings fairly routine here.
What the filings say
In its latest report (10-Q, filed Nov 13, 2026), $CPIX earned $77.8M over the quarter to Sep 30, 2026 on revenue of $2.2M (-75.5% QoQ). Operations used $942K of cash over the nine months to Sep 30, 2026 — about $105K a month — against $80.6M in cash on Sep 30, 2026. At that pace the cash covers about 63.9 years. Total liabilities were $41.6M against $80.6M of cash on Sep 30, 2026. The company filed an 8-K — the form for material events — on Nov 10, the same day as this story; it is $CPIX's own account and the first thing to read. Figures are as filed with the SEC; the $CPIX page has the full statements.
How much coverage it is getting
Wook has filed 5 stories on Cumberland Pharmaceuticals in the last 30 days, 0 of them this week. None came this week, so coverage has gone quiet. Going by their wording, 0 read bullish, 5 neutral and 0 bearish. This one reads neutral too, in line with most of them. Seeking Alpha wrote 4 of the 5 (80%), so the count reflects one outlet's output more than broad attention.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
For the receipts, the $CPIX page has the full chart, filings, and valuation model. One outlet dominates the coverage, so reading another is the quickest check on whether it's being confirmed or just repeated. Wook AI can pull live figures and run the numbers on request — how far $CPIX is from its high, or how this week's coverage compares.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Seeking Alpha published this on November 10, 2026. $CPIX has moved +8.61% ($5.34 to $5.80). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
